Intermittent fasting, popularized by the 5:2 diet and 16:8 variations, promises significant health benefits, including weight loss and disease prevention. While early studies in mice showed remarkable results, human trials present a more nuanced picture.
Experts like Krista Varady, a professor of nutrition, state that the diet is "oversold." Research suggests that intermittent fasting does not offer superior weight loss compared to traditional calorie-restricted diets. Studies often cited in favor of fasting can be flawed, with James Betts, a professor of metabolic physiology, noting significant errors in some pro-fasting research.
While intermittent fasting can lead to metabolic improvements like increased insulin sensitivity, these benefits largely mirror those seen with any diet that results in weight loss. Stephan Herzig, a researcher at Heidelberg University Hospital, found no unique cellular changes from intermittent fasting that could form the basis for new drugs. Some studies even suggest certain fasting methods can negatively impact metabolism by causing muscle loss.
Claims of cognitive benefits are similarly overstated. While prolonged fasting in mice has shown improvements, shorter, less intense regimens common in human practice appear to have no significant effect on cognition. Preliminary research on cancer suggests fasting may reduce treatment side effects, potentially allowing patients to adhere to chemotherapy schedules, but evidence for direct anti-cancer effects in humans is still developing.
Ultimately, for many of the broader claims regarding longevity and disease prevention, a trend is emerging: the more rigorous the study, the less significant the findings. The initial enthusiasm based on animal trials may not fully translate to human health outcomes.